Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - Other
Ratios

Protagonist Therapeutics (PTGX) Long-Term Debt Issuances (2019 - 2023)

Protagonist Therapeutics (PTGX) has disclosed Long-Term Debt Issuances for 4 consecutive years, with $24.3 million as the latest value for Q1 2023.

  • Quarterly Long-Term Debt Issuances rose 66.99% to $24.3 million in Q1 2023 from the year-ago period, while the trailing twelve-month figure was $24.3 million through Dec 2023, up 66.99% year-over-year, with the annual reading at $24.3 million for FY2023, 66.99% up from the prior year.
  • Long-Term Debt Issuances hit $24.3 million in Q1 2023 for Protagonist Therapeutics, up from $14.6 million in the prior quarter.
  • In the past five years, Long-Term Debt Issuances ranged from a high of $34.0 million in Q3 2019 to a low of -$24.7 million in Q4 2019.
  • Historically, Long-Term Debt Issuances has averaged $12.2 million across 4 years, with a median of $16.7 million in 2020.
  • Biggest YoY gain for Long-Term Debt Issuances was 176.2% in 2020; the steepest drop was 81.23% in 2020.
  • Year by year, Long-Term Debt Issuances stood at -$24.7 million in 2019, then skyrocketed by 176.2% to $18.8 million in 2020, then decreased by 22.77% to $14.6 million in 2022, then skyrocketed by 66.99% to $24.3 million in 2023.
  • Business Quant data shows Long-Term Debt Issuances for PTGX at $24.3 million in Q1 2023, $14.6 million in Q1 2022, and $18.8 million in Q4 2020.